3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
CNS
1
Conditions
Neuroblastoma
7
Recurrence
1
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Neoplasms
1
Ganglioneuroblastoma
1
Interventions
Everolimus
2
vandetanib
1
spartalizumab
1
gallium Ga 68 dotatate
1
fludarabine phosphate
1
cixutumumab
1
Specimen Handling
1
Salts
1
Octreotide
1
Magnetic Resonance Spectroscopy
1
Interleukin-13
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Biopsy
1
Acetates
1
3-Iodobenzylguanidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Paraganglioma
×
3-Iodobenzylguanidine
×
Clear all
NCT01941849
2015-12-21
VIBRaNT
University College, London
Phase 1
Withdrawn